Filtered By:
Source: Neurology
Condition: Ischemic Stroke

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 1519 results found since Jan 2013.

Increased Cysteinylated Albumin is Associated with More Favorable Outcomes in Ischemic Stroke Patients, A Reflection of Collateral Circulation? (P1.261)
Conclusions:Increasing levels of cysteinylated albumin were associated with more favorable discharge mRS and less mortality. Cysteinylated (oxidized) albumin may reflect the presence of collateral circulation in equilibrium with the peripheral circulation from where venous blood samples were obtained for this study.Disclosure: Dr. Bartt has nothing to disclose. Dr. Leonard has nothing to disclose. Dr. Bar-Or has nothing to disclose. Dr. Rael has nothing to disclose. Dr. Bar-Or has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Bartt, R., Leonard, J., Bar-Or, R., Rael, L., Bar-Or, D. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research

The relationship between chemerin levels and carotid intima-media thickness in patients with ischemic stroke (P1.262)
Conclusions:Consequently, this study showed that serum chemerin levels may play role in atherosclerosis and ischemic stroke.Study Supported by: Fırat University (FÜBAP)Disclosure: Dr. Demir has nothing to disclose. Dr. Atas has nothing to disclose. Dr. Aytaç has nothing to disclose. Dr. Gonen has nothing to disclose. Dr. Erten has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Demir, C., Ataş, I., Aytac, E., Gonen, M., Erten, Z. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research

Preconditioned M2 microglia by oxygen-glucose deprivation promote functional recovery in ischemic rats (P1.264)
Conclusions:Intravascular administration of M2 microglia preconditioned by OGD might be a novel therapeutic strategy against ischemic stroke.Disclosure: Dr. Kanazawa has nothing to disclose. Dr. Miura has nothing to disclose. Dr. Toriyabe has nothing to disclose. Dr. Koyama has nothing to disclose. Dr. Hatakeyama has nothing to disclose. Dr. Ishikawa has nothing to disclose. Dr. Nakajima has nothing to disclose. Dr. Onodera has nothing to disclose. Dr. Nishizawa has nothing to disclose. Dr. Shimohata has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Kanazawa, M., Miura, M., Toriyabe, M., Koyama, M., Hatakeyama, M., Ishikawa, M., Nakajima, T., Onodera, O., Nishizawa, M., Shimohata, T. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research

Orosomucoid-1 Protein Dynamics Following Ischemic Stroke in Humans and Mice (P1.265)
Conclusions:ORM-1 is a sexually dimorphic protein involved in the early (<24 hour) response to ischemic stroke. This research demonstrates that sex differences exist in post-stroke ORM-1 protein dynamics, and serves as an initial step in determining the mechanism of ORM-1 in the ischemic stroke response and its potential as a future therapeutic target for both sexes.Study Supported by:NIH Grant 5 R01 NS055215 09, and Hartford Hospital, Hartford, CT.Additional thanks to Sharon DiMauro, Lori Capozzi, and to the Scientific Research Committee at the University of Connecticut School of Medicine.Disclosure: Dr. Mistry has not...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Mistry, H., Levy, M., Roy-OReilly, M., McCullough, L. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research

Analysis of Run Sheets of EMS Serving a Metropolitan Comprehensive Stroke Center (P1.268)
Conclusions:Patients with acute stroke transported by EMS have better quality metrics and higher chance of receiving acute treatment. EMS documented assessment allows for the diagnosis or stroke in general but cannot identify LVO because the assessment of cortical signs is very limited.Disclosure: Dr. Hussein has nothing to disclose. Dr. Kashyap has nothing to disclose. Dr. Erickson has nothing to disclose. Dr. Forsberg has nothing to disclose. Dr. Burnett has nothing to disclose. Dr. Stanfield has nothing to disclose. Dr. Wewerka has nothing to disclose. Dr. Terwilliger has nothing to disclose. Dr. Hanson has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Hussein, H., Kashyap, B., Erickson, L., Forsberg, A., Burnett, A., Stanfield, S., Wewerka, S., Terwilliger, A., Hanson, L. Tags: Pre-Hospital Stroke, Tele-Stroke, and mHealth Source Type: research

Walk-in versus ems-prenotified stroke codes-time targets in a comprehensive stroke center (p1.271)
Conclusions:Walk-in strokes had significant delay in LKW to arrival, highlighting the need for community education in recognizing symptoms of stroke. People with larger strokes(higher NIHSS) tend to present via EMS. Significant delays in door to CT and stroke-code in walk-in strokes, demonstrates need for early stroke symptom recognition in the ER. EMS education and pre-notification improves likelihood of tPA administration.Disclosure: Dr. Kaur has nothing to disclose. Dr. Gudlavalleti has nothing to disclose. Dr. Schleier has nothing to disclose. Dr. Vallelunga has nothing to disclose. Dr. Onyan has nothing to disclose. D...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Kaur, G., Gudlavalleti, A., Schleier, J., Vallelunga, M., Onyan, J., Latorre, J. Tags: Pre-Hospital Stroke, Tele-Stroke, and mHealth Source Type: research

Evaluation of NIHSS-Onset to Groin Time (OGT) and Prehospital Acute Stroke Severity Scale (PASS)-OGT scores in prediction of outcomes after Endovascular Treatment in Acute Ischemic Stroke patients: A Retrospective Single-Center Study (P1.272)
Conclusions:Our study indicates NIHSS–OGT and PASS-OGT scores have a linear relationship with discharge mRS and can reliably predict early clinical outcomes after ET. Further confirmation with randomized control trials is needed.Disclosure: Dr. Niazi has nothing to disclose. Dr. E-Ghanmh has nothing to disclose. Dr. Reichwein has nothing to disclose. Dr. Cockroft has nothing to disclose. Dr. Ermak has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Niazi, M., El-Ghanem, M., Reichwein, R., Cockroft, K., Ermak, D. Tags: Pre-Hospital Stroke, Tele-Stroke, and mHealth Source Type: research

Evaluation and Validation of Prehospital Acute Stroke Scale to Predict Large Vessel Occlusion in Patients with Proven Large Vessel Occlusion- Single Center study in US (P1.274)
Conclusions:The PASS tool is simple, quick, and easy to perform and has high sensitivity in AIS patients with LVO. To assess its value and efficacy in real time it should be implemented into EMS systems and be performed in the pre-hospital setting.Disclosure: Dr. E-Ghanmh has nothing to disclose. Dr. Niazi has nothing to disclose. Dr. Reichwein has nothing to disclose. Dr. Ermak has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: El-Ghanem, M., Niazi, M., Reichwein, R., Ermak, D. Tags: Pre-Hospital Stroke, Tele-Stroke, and mHealth Source Type: research

Lytic therapy and mechanical thrombecomty over tele-stroke, a comprehensive stroke center experience (P1.275)
Conclusions:Our study shows that our Tele stroke program had evolved over time to involve more sites throughout the state of South Carolina. Post IV tPA sICH was within the expected range.Disclosure: Dr. Al Kasab has nothing to disclose. Dr. Debenham has nothing to disclose. Dr. Jones has nothing to disclose. Dr. Holmstedt has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Kasab, S. A., Debenham, E., Jones, D. J., Holmstedt, C. A. Tags: Pre-Hospital Stroke, Tele-Stroke, and mHealth Source Type: research

Safety and Efficacy of Thrombolysis in Telestroke for the Extended Time Window (P1.276)
Conclusions:There was no significant difference in sICH or mRS for patients who received thrombolysis through telestroke before 3 hours compared to those that received it in 3 to 4.5 hours. This data suggests that it is safe and efficacious to give IV tPA with telemedicine from 3 to 4.5 hours.Disclosure: Dr. Steinberg has nothing to disclose. Dr. Kenmuir has nothing to disclose. Dr. Jovin has received personal compensation for activities with Codman and Neuravi as a consultant. Dr. Jovin has received compensation for serving on Anaconda, Silk Road, Blockade Medical. Dr. Wechsler has received personal compensation for activ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Steinberg, A., Kenmuir, C., Jovin, T., Wechsler, L., Jadhav, A. Tags: Pre-Hospital Stroke, Tele-Stroke, and mHealth Source Type: research

Door to Page Time to Initiate a Telemedicine Consult Varies Among Spoke Hospitals for Acute Stroke (P1.277)
Conclusions:Bed capacity, pre-notification, location in a MUA, and in-house neurology availability are associated with prolonged DTP. Further investigation is needed to understand why these factors affect DTP. While retrospective in nature, our study confirms the utility of pre-notification for spoke hospitals. In addition, standardized acute stroke metrics over TM are needed.Disclosure: Dr. Randhawa has nothing to disclose. Dr. Jagolino has nothing to disclose. Dr. Ankrom has nothing to disclose. Dr. Bozorgui has nothing to disclose. Dr. Bambhoroliya has nothing to disclose. Dr. Vahidy has nothing to disclose. Dr. Cossey ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Randhawa, J., Jagolino, A., Ankrom, C., Bozorgui, S., Bambhoroliya, A., Vahidy, F., Cossey, T., Savitz, S., Wu, T.-C. Tags: Pre-Hospital Stroke, Tele-Stroke, and mHealth Source Type: research

Quality Improvement in Telestroke Interactions (P1.280)
Conclusions:The use of an efficient, widely accessible online NIHSS review improves remote provider examination accuracy and confidence, and telestroke neurologist provider satisfaction.Study Supported by: NADisclosure: Dr. Nasr has nothing to disclose. Dr. Braksick has nothing to disclose. Dr. Brown has nothing to disclose. Dr. Hocker has received personal compensation for writing a Continnuum and being interviewed for Continuum Audio. Dr. Ho has received research support from SAGE Therapeutics
Source: Neurology - April 17, 2017 Category: Neurology Authors: Nasr, D., Braksick, S., Brown, R., Hocker, S. Tags: Pre-Hospital Stroke, Tele-Stroke, and mHealth Source Type: research

Hyperacute Carotid Stenting for Acute Ischemic Stroke After Systemic Thrombolysis with IV rt-PA (P1.282)
Conclusions:These 2 cases demonstrate a successful use of hyperacute carotid stenting and antiplatelet load in patients who received systemic thrombolysis with IV rt-PA. Both had excellent outcomes and no complications. This management may be considered in patients with similar clinical and imaging characteristics.Disclosure: Dr. Marulanda-Londoño has nothing to disclose. Dr. DeLeon-Bendetti has nothing to disclose. Dr. Ortiz has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Marulanda-Londono, E., DeLeon-Bendetti, A., Ortiz, G. Tags: Cerebrovascular Disease Case Reports I Source Type: research

Successful endovascular stroke therapy in a 103-year-old woman (P1.284)
Conclusions:The patient in our report presented within 3 h of acute stroke onset secondary to a large vessel occlusion and had very favorable imaging without any early ischemic changes. She also lived an independent functional life with a robust family support structure. To our knowledge, this is the oldest patient to undergo a successful stroke intervention, and the purpose of this report was to document that in carefully selected patients, endovascular therapy may become a feasible option. Other than the clinical and imaging criteria typically utilized for patient selection, including their social, cognitive, and functio...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Duru, U., Boo, S., Rai, A., Smith, M. Tags: Cerebrovascular Disease Case Reports I Source Type: research

4-year-old boy with acute ischemic stroke treated with intravenous tissue plasminogen activase. (P1.285)
Conclusions:The TIPS trial is underway, which utilizes a classic safety dose finding method to select a safe dose of IV tPA. The child in our case was successfully treated with a dose of 0.75 mg/kg of IV tPA. It has been suggested the appropriate dose may actually be higher than the standard used in adults due to the developmental trajectory of the fibrinolytic system during childhood, as children have lower endogenous tPA and higher plasminogen activator inhibitor-1 levels.Disclosure: Dr. Derani has nothing to disclose. Dr. Kassab has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Derani, T., Kassab, M. Tags: Cerebrovascular Disease Case Reports I Source Type: research